Patents by Inventor Ho Sang Shin

Ho Sang Shin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for using information on complex biomarker group to diagnose lung cancer in a subject and diagnostic kit and computing system using the same
    Patent number: 10663469
    Abstract: A method for diagnosing lung cancer in a subject by using a complex biomarker group is provided. The method includes steps of: (a) a computing system (1) acquiring a model M by using expression level data by individual biomarkers in the complex biomarker group and then (2) acquiring expression level data by the individual biomarkers measured from a biological specimen of the subject or their processed data Bk; and (b) the computing system determining whether lung cancer is detected in the subject by using the acquired data of the subject by referring to the model M; wherein the complex biomarker group includes CEA, HE4, ApoA2, TTR, sVCAM-1 and RANTES.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: May 26, 2020
    Assignee: BioInfra Life Science Inc.
    Inventors: Chul Woo Kim, Yong Dai Kim, Yong Sung Shin, Eun Hee Yeon, Kyung Nam Kang, Ho Sang Shin, Oh Ran Kwon
  • METHOD FOR USING INFORMATION ON COMPLEX BIOMARKER GROUP TO DIAGNOSE LUNG CANCER IN A SUBJECT AND DIAGNOSTIC KIT AND COMPUTING SYSTEM USING THE SAME
    Publication number: 20180067118
    Abstract: A method for diagnosing lung cancer in a subject by using a complex biomarker group is provided. The method includes steps of: (a) a computing system (1) acquiring a model M by using expression level data by individual biomarkers in the complex biomarker group and then (2) acquiring expression level data by the individual biomarkers measured from a biological specimen of the subject or their processed data Bk; and (b) the computing system determining whether lung cancer is detected in the subject by using the acquired data of the subject by referring to the model M; wherein the complex biomarker group includes CEA, HE4, ApoA2, TTR, sVCAM-1 and RANTES.
    Type: Application
    Filed: February 10, 2017
    Publication date: March 8, 2018
    Inventors: Chul Woo Kim, Yong Dai Kim, Yong Sung Shin, Eun Hee Yeon, Kyung Nam Kang, Ho Sang Shin, Oh Ran Kwon
  • Method for monitoring, diagnosing, and screening cancer through measuring the concentration of des-R prothrombin activation peptide fragment F2 (des-R F2) in a serum
    Patent number: 8435748
    Abstract: The present invention relates to a method for diagnosis and screening of cancer by measuring the expression of des-R prothrombin activation peptide fragment F2 (des-R F2) in serum, more precisely, des-R-prothrombin activation peptide fragment F2 which is the protein marker down-regulated specifically in liver cancer, breast cancer, and stomach cancer, and a method for diagnosis and screening of liver cancer, breast cancer, and stomach cancer by quantifying the protein marker. The protein marker of the present invention can be effectively used for diagnosis and screening of liver cancer, breast cancer and stomach cancer by comparing the expression of the said protein marker in a normal subject with that of a liver cancer, breast cancer, or stomach cancer patients.
    Type: Grant
    Filed: March 13, 2009
    Date of Patent: May 7, 2013
    Assignee: Bioinfra Inc.
    Inventors: Chul Woo Kim, Pil Je Park, Yong-Sung Shin, Kil Hyon Lee, Ho Sang Shin, Byoung-Kwon Kim
  • METHOD FOR MONITORING, DIAGNOSING, AND SCREENING CANCER THROUGH MEASURING THE CONCENTRATION OF DES-R PROTHROMBIN ACTIVATION PEPTIDE FRAGMENT F2 (DES-R F2) IN A SERUM
    Publication number: 20110086404
    Abstract: The present invention relates to a method for diagnosis and screening of cancer by measuring the expression of des-R prothrombin activation peptide fragment F2 (des-R F2) in serum, more precisely, des-R-prothrombin activation peptide fragment F2 which is the protein marker down-regulated specifically in liver cancer, breast cancer, and stomach cancer, and a method for diagnosis and screening of liver cancer, breast cancer, and stomach cancer by quantifying the protein marker. The protein marker of the present invention can be effectively used for diagnosis and screening of liver cancer, breast cancer and stomach cancer by comparing the expression of the said protein marker in a normal subject with that of a liver cancer, breast cancer, or stomach cancer patients.
    Type: Application
    Filed: March 13, 2009
    Publication date: April 14, 2011
    Applicant: BIOINFRA INC.
    Inventors: Chul Woo Kim, Pil Je Park, Yong-Sung Shin, Kil Hyon Lee, Ho Sang Shin, Byoung-Kwon Kin